After an IV infusion of Wharton’s jelly derived umbilical mesenchymal stem cells, the first place to where Stem Cells go is the lungs. This is what makes them very effective for the treatment of pulmonary disease.

Lung diseases are very complex and while several lung diseases, especially asthma, are now able to be relatively safely and effectively treated, considerable therapeutic gaps remain, particularly for degenerative and fibrotic lung diseases in which they diminish symptoms but cannot prevent its progress or regenerate physiological lung structure or function.

Recently Stem Cell therapy is being studied, and in any studies has in fact been shown to be effective in the treatment of COVID 19 and in reducing the effects of long Covid symptoms.

Currently, there is no definitive therapy for COVID-19 or associated complications. Wharton’s Jelly derived umbilical mesenchymal Stem Cell therapy provides an option due to their immunomodulatory effects and tissue repair and regeneration abilities. Studies have demonstrated that use of Stem Cells can reduce symptoms associated with SARS-CoV-2 infection, eliminate fluid buildup, and act as a regenerative technique for alveolar damage; all in a safe and effective way.